On March 5, 2025 Immorta Bio Inc., a leader in longevity-focused biotechnologies, reported acceptance of its poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) Spring Scientific, Cellular Therapy for Solid Tumors in San Diego, CA, on March 12-13, 2025 (Press release, Immorta Bio, MAR 5, 2025, View Source [SID1234650919]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present molecular and cellular mechanisms by which its First-In-Class Senolytic Immunotherapy specifically kills senescent cells associated with cancer initiation, progression, and protection.

"We plan to present data demonstrating regression of cancers in animal models of glioma, lung, breast, and pancreatic cancers using our SenoVax approach," said Dr. Thomas Ichim, President and Chief Scientific Officer of Immorta Bio. "SenoVax is an autologous senescent cell pulsed dendritic cell product for which we plan to start clinical trials for lung cancer shortly.

The poster is a result of Immorta Bio collaboration with esteemed institutions, including the University of California San Diego, George Washington University, Cedars-Sinai, and Calidi Biosciences.

"The Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) is the world’s leading organization dedicated to the advancement of cancer immunotherapy. For us to be selected to present in front of such a distinguished audience is significant accomplishment and indicates acceptance of our "paradigm-shifting" approach in that we kill cancer by targeting the senescent cells surrounding it," said Dr. Boris Reznik, Chairman and CEO of Immorta Bio. "Based upon our preclinical data we anticipate to also see SenoVax to reduce systemic senescent cells load resulting in associated "antiaging" effects in treated patients."